Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the
development of molecular diagnostic tests for cancer, announced today
the appointment of David Gandara, M.D. to its Board of Directors. Dr.
Gandara, a well-known expert in lung cancer and developmental
therapeutics, brings significant medical and clinical development
expertise in oncology to Response Genetics. He is currently a Professor
of Medicine at the University of California, Davis School of Medicine.
He is also the Director of Clinical Research, and the Director of the
Thoracic Oncology Program at the U.C. Davis Cancer Center.
Dr. Gandara brings more than 30 years of clinical and medical experience
to Response Genetics. He is a member of the Board of Directors of the
International Association for the Study of Lung Cancer and the Addario
Foundation. He served as a member of the Board of Directors of the
American Society of Clinical Oncology (ASCO) and as secretary-treasurer.
Dr. Gandara is also a member of many professional committees, including
the NCI Investigational Drug Steering Committee and the NCI Science
Correlates Committee. He currently is the Chair of the Southwest
Oncology Group´s Lung Committee (SWOG). In
addition, Dr. Gandara is also an accomplished author who has published
more than 225 articles, written 10 book chapters, and authored more than
255 abstracts and 125 presentations.
"Response Genetics is honored to welcome Dr.
Gandara to our Board of Directors," said
Kathleen Danenberg, CEO and President of Response Genetics, Inc. "We
believe Dr. Gandara´s experience and expertise
in oncology and developmental therapeutics will add considerable depth
to our Board. We are confident that Dr. Gandara will provide invaluable
guidance as we work aggressively to execute our business goals."
"I am excited to join Response Genetics and
welcome the opportunity to contribute to the company´s
growth and to help advance the company´s
products," commented Dr. Gandara. "I
believe the company´s diagnostic cancer
products have the potential to significantly improve outcomes in
individuals with cancer."
Dr. Gandara holds a B.A. from the University of Texas and an M.D. with
honors from the University of Texas Medical Branch in Galveston, TX.
About Response Genetics, Inc.
Response Genetics, Inc. ("RGI") (the "Company")
(NASDAQ: RGDX) is engaged in the research and development of
pharmacogenomic cancer diagnostic tests based on its proprietary and
patented technologies. RGI´s technologies enable extraction and analysis
of genetic information from genes derived from tumor samples stored as
formalin-fixed and paraffin embedded specimens. RGI currently generates
revenue primarily from the sales of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry. The Company was founded in 1999 and its
principal headquarters are located in Los Angeles, California. For more
information, please visit www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press
release and the statements of representatives of RGI related thereto
contain or may contain, among other things, certain forward-looking
statements, within the meaning of the Private Securities Litigation
Reform Act of 1995.
Such forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation
statements with respect to the Company´s plans, objectives, projections
expectations and intentions, such as the ability of the Company to
analyze cancer samples, the potential for using the results of this
research to develop diagnostic tests for cancer, the usefulness of
genetic information to tailor treatment to patients, the ability of the
Company to make its ResponseDx:Lung? and
ResponseDX:Colon? tests available in a number
of institutions, and other statements identified by words such as
"projects," "may," "could," "would," "should," "believes," "expects,"
"anticipates," "estimates," "intends," "plans" or similar expressions.
These statements are based upon the current beliefs and expectations of
the Company´s management and are subject to significant risks and
uncertainties, including those detailed in the Company´s filings with
the Securities and Exchange Commission. Actual results, including
without limitation, actual sales results, if any, or the application of
funds, may differ from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks and
uncertainties that are subject to change based on various factors (many
of which are beyond the Company´s control). The Company undertakes no
obligation to publicly update forward-looking statements, whether
because of new information, future events or otherwise, except as
required by law.
